Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Research Foundation of State University of New York et al v. Mylan Pharmaceuticals Inc.
Case Number:
1:09-cv-00184
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 22, 2012
Judge Bars Mylan's Oracea Generic In Galderma IP Case
A Delaware federal judge on Friday barred Mylan Pharmaceuticals Inc. from selling a generic version of Galderma Laboratories Inc.'s rosacea drug Oracea, even though the patent Mylan was found to have infringed was issued after its generic received government approval.
-
June 29, 2010
Mylan Barred From Selling Generic Oracea
A federal judge has approved dermatology company Galderma Laboratories Inc.'s bid for a preliminary injunction preventing Mylan Pharmaceuticals Inc. from selling a generic version of rosacea drug Oracea.